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1008-I 25 Differing Clinical Characteristics Among Black and 
White Patients Referred for Treatment of Pulmonary 
Hypertension 
Richard A. Krasuski, Andrew Wang, J. Kevin Hamson, Michelle Johnson, Cynthia Pierce, 
Thomas M. Bashore, Wilford Hall Medical Center, San Antonio, TX, Duke Unwersity 
Medical Center, Durham, NC 
Background: A recent review of death ceriiflcates from the Center for Disease Control 
and Prevention revealed that black men and women have a substantially higher mortality 
from primary pulmonary hypertension than whites. Furthermore, this discrepancy has 
widened over the past two decades and the reason for this remains unknown. 
Methods: We reviewed the baseline clinical Information, echocardiograms, and hemody 
namic characteristics of 91 patients (69 whites and 22 blacks) with pulmonary hyperten- 
sion referred to a tertiary medical center for vasodilator testing prmr to initiation of 
definitive therapy. All patients had pulmonary vasodilator response assessed with 40 
ppm of inhaled nitric oxide (iNO). 
Results: Though black patients tended to be younger (49 +I- 12 vs. 56 +/-I4 years of 
age, p=O.O63), black and wh!te patients were similar in gender (18% vs. 22% female), 
underlying diagnosis (-59% vs. 58% carrying a diagnosis of primary pulmonary hyper- 
tension), and baseline NYHA function class (2.8 vs. 2.9). Echocardiograms revealed 
larger right ventricles (p<O.OQl) with more extensive hypocontactility (p=O.O06) and 
greater tricuspid regurgitation (3.1 +/- 1.2 vs. 2.2 +I-1.2, p=O.O04) in black patients. 
Hemodynamics were notable for higher mean right atrial pressures (14 +/- 7 vs. 10 +/- 6 
mm Hg, p=O.O46) in black patients despite similar mean pulmonary pressures (51 +/- 12 
vs. 46 +I- 15 mm Hg, p=O.l51). The mean % reduction in pulmonary pressures with iN0 
was greater in white patients but did not reach stabstical significance (17% vs. 12%, 
p=O.l26). 
Conclusion: In a group of pulmonary hypertension patients referred for vasodilator test- 
ing, black patients appeared to have mole advanced pulmonary hypertension wth 
greater ewdence of end-organ damage by echocardiography. This suggests either more 
rapid pmgrewon of disease or delayed diagnosis and/or referral in blacks with pulmo- 
nary hypertension and may explain the discrepancy in mortality seen between blacks 
and whites with this disorder. 
1008-l 26 ORS Duration Predicts Survival in Patients With 
Pulmonary Arterial Hypertension 
Maninder S. Bedi, Jessica Spates-Panyon, Michael A. Mathier, Guy A. MacGowan, 
Dennis M. McNamara, Srinivas Murali, University of Pittsburgh, Pittsburgh, PA 
Pulmonary Arterial Hypertension (PH) is a progressive disease associated with right ven- 
tricular (RV) remodeling, systolic dysfunction and death. Both incomplete and complete 
right bundle branch block are frequently observed on surface electrocardiograms (EKG) 
in PH patients. QRS and QTc duration are directly related to mortality in patients (pts) 
with left ventricular (LV) systolic dysfunction. Whether these EKG intervals influence out- 
come in pts with RV failure due to PH is not known. 
Methods: We prospectively evaluated EKG and clinical outcomes in 70 PH pts (Mean 
age 48.5kll.6 years, 81.7% female, LVEF 55&%, NYHA Class Ill/IV 56/44%, Primary 
PH 66%, Secondary PH 33%) treated with chronic epoprostenol (E) therapy. QRS and 
QTc were measured at baseline (prior to E therapy) and pts were followed for 824~527 
days (range i-1868 days). 
Results: Right bundle branch block was incomplete in 44 (63%) and complete in 9(13%) 
pts. Demographic variables were comparable in pts with QRS duration ~100 ms and > 
IOOms or QTc duration < 450”s or > 450 ms. In followup, 21 pts (29.6%) died and 13 
(I 6.6%) underwent transplantation. One, 2 and 4 year transplant free survival for QRS < 
lOO/ >lOOms was 74/55/44% and 65/38/19% (p=O.O4) and for QTc < 450/ >450 ms was 
75168145% and 53155140% (p=O.5) respectively. 
Conclusion: As seen with LV systolic dysfunction, in pts with RV systolic dysfunction 
due to PH, a QRS duration >lOOms is associated with poorer survival. QTc interval 
>450ms. on the other hand, does not appear to affect suw~val. 
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1008-127 Prognostic Value of Brain Natriuretic Peptide and 
Cardiac Troponin T in Patients With Confirmed 
Pulmonary Embolism: Changes After Treatment 
loOr I. Tulevski, Jasper W. M. Mulder, Marye ten Wolde. Dirk J. van Veldhulsen, Harry 
Bullar, Ernst E. van dar Wall, Barbara J M. Mulder. Academic Medical Center, 
Amsterdam, The Netherlands 
Background- The aim of the present study was to assess the changes in plasma levels 
of the brain natriuretic peptide (BNP) and cardiac troponin T (cTnT) before and after 
traatmant in patients with acute PE. Methods- BNP and cTnT levels were measured in 
31 Patients (age 56(16)) with acute PE as diagnosed by high probability lung scintlgraphy 
or PUlmOnav angiography. Twenty seven healthy age-matched volunteers served as 
controls (age 42(12)). Blood from all patients was obtained dunng the first hour of pra- 
sentatlon. All patients were treated with intravenous admission of heparin. After 30 days 
Of follow-up. regardless of additional treatment, the second blood samples were 
acquired. None of the patients had renal impairment, atrial arrhytmia, preexlstmg RV 
pathology or left ventricular dysfunction. 
Results- Patients with acute PE had significantly higher BNP plasma levels and cTnT 
than the controls. (BNP 48.2 + 78.3 pmol/L versus 3.1 * 3.7 pmollL; p=O.O04 and cTnT 
0.16 * 0.017 pmol/L versus 0.1 + 0 pmol/L; p< 0.05). Out of 31 patients, the 6 patients 
who died during the follow up had significantly higher plasma BNP levels at presentation 
compared to the survwors (BNP 129.5 * 139.1 versus 28.7 * 39.8; p= 0.003). In the 
group of survivors the plasma BNP levels after 30 days were significantly lower com- 
pared to the first visit (BNP 10.3 * 15.7 pmol/L versus 28.7 f 39.8 pmol/L; ~~0.02 and 
ANP 7.0 * 8.0 pmol/L versus 10.3 * 15.4 pmol/L; p=ns). CTnT showed similar 
raSUltS.COnClUSiOnS- These results showed a significant decrease of BNP and cTnT 
after treatment of patients with acute PE. There was also a significant relationship 
between presenting BNP and cTnT levels, and 30.day mortality in patlants with acute 
PE. 
1008-l 28 Right Atrial Thrombus: A Comparison Between Freely 
Mobile and Partially Mobile Thrombus 
Sundeep Bhatia, Seong H. Park, Roger L. Click, James B. Seward, Jae K. Oh, Mayo 
Clinic, Rochester, MN 
Background: Mobile right atrial thrombus (RAT) is a potentially fatal echocardiographic 
finding. The distinction between freely mobile and partially mobile RAT may influence 
treatment strategy and outcome. An optimal treatment strategy has yet to be established. 
Methods: A total of 77 patients wth mobile RAT between January 1, 1984 and July 15, 
2002 were studied. Freely mobile RAT, characterized by a typical ‘“popcorn” or serpigi- 
nous appearance, was defined as type I if a major portion of the mass moved freely 
within the right atrium and crossed the tricuspid valve. Partially mobile RAT, with a broad 
attachment to an intracardiac structure or foreign body, was defined as type II. Cllnical 
history and diagnostic studies wew reviewed to document treatment choice and out- 
come. Mortality is repolted as within 14 days in-hospital from all causes. 
Resu/ts:Type I RAT was Identified in 16 males and 15 females with a mean age of 59 * 
17.1 years and type II RAT was identified in 24 males and 22 females with a mean age of 
51 * 25.1 years. Mortality in patients with type I RAT was higher than those with type II 
RAT. (32.3% “wsw 8.7%, p=O.O09).Table 1 
Treatment stwtcgy and OU~COIIIC 
Heparin Thrombolytics Surgery None 
No. Mortality NO. Mortality No. Mortality No. Mortality 
Type I 20 7 (35%) 8 2 (25%) 2 0 (0%) 1 1 (100%) 
Type II 28 3 (10.7%) 4 0 (0%) 6 O(O%) 8 1(12.5%) 
Conclusion: 1) Mortality is significantly higher m patients with type I RAT; 2) Patients 
wth type I RAT should be managed emergently with either thrombolytlcs 01 surgical 
intewention; whereas patients wth type II RAT may initially be managed with standard 
antlcoagulatlon followed by thrombolytics or surgical intervention for persistent thrombus 
or unstable hemodynamics. 
1008-l 29 High Incidence of Left Atrial Appendage Thrombus in 
End-Stage Renal Disease Patients Receiving 
Maintenance Hemodialysis 
Masato Nlshimura, Tetsuya Hashimoto, Hlroyuku Kobayashi, Toyofumi Fukuda, Koji 
Okino, Noriyuki Yamamoto, Toshihiko One. Toujinkai Hospital, Kyoto, Japan 
Background: lntracardlac sources of cerebrovascular ischemic events reportedly account 
for 15 to 20% of the strokes in the general population. However, no study has determined 
the incidence of intracardiac thrombus formation in hemodialysis patients. In this study, 
we determined the incidence of intracardiac thrombus formation in maintenance hemodi- 
alysis patients. 
Methods: Transesophageal echocardiography was performed in 215 patients wth end- 
stage renal disease undergoing maintenance hemodialysis (125 males, 90 females; 
mean age: 60 + 9 years). Patients with a current or previous history of atrial fibrillation or 
with cardiovascular disease were excluded from this study. 
Results: Thrombus was found in the left atrial appendage in 711215 patients (33%). 
Based on multiple logistic regression analyses, the relative risk of the presence of throm- 
bus was increased in patients on chronic antiplatelet therapy (odds ratio: 4.268) and in 
those with diabetes mellitus and a low hematocrit (0.3 or less; odds ratlo. 7.173) Other 
clinlcal parameters including gender, age, duration of hemodialysis, blood pressure, left 
ventricular dimension, smoking habit, or type of antlcoagulation drug used during dlaly- 
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sis. were not associated with the incidence of left atrial appendage thrombus. 
Conclusions: Maintenance hemodialysis patients have left atrial appendage thrombus at 
an unexpectedly high Incidence. The chronic use of antiplatelet drugs and the concomi- 
tant presence of diabetes mellltus and a low hematocrit may be Involved in left atrial 
appendage thrombus form&on. 
1008-i 30 Comparison of Echocardiographic Indices of Right 
Ventricular Obstruction in Pulmonary Embolism 
Nicolas Mansencal, Thierry Joseph, Antoine Vieillard-Baron. Salah D. Qanadli, Fran~o~s 
Jardin. Pascal Lacombe, Gutllaume Jondeau, Olivier Dubourg, H&pita1 Ambrolse Par& 
Boulogne. France 
Background: Different echocardiographlc parameters have been described in pulmonary 
embolism (PE). The ouroose of this studv was to determine the most accurate echocar- 
dlographic index of right ventricular obstruction in acute PE. 
Methods: Fiftv-seven consecutive oatients (mean aae 56 * 17 vears) oresentlno with PE 
I  ,  , .  
quantified by angiographic Miller index were studied. Following echocardiographic 
parameters were systematically assessed: 1) right to left ventricular end-dlastollc diame- 
ter ratlo (RVEDD/LVEDD) in parasternal long-axis view, 2) right to left ventricular end- 
diastolic area ratio (RVEDAILVEDA) in apical 4-chamber view, 3) systolic pulmonary 
arterial pressure @PAP) using CW Doppler. 
Results: The correlations between echocardiography and Miller Index were 0.52 for the 
AVEDD/LVEDD, 0.72 for the RVEDA/LVEDA and 0.52 for SPAP. Using Miller index 
higher than 40% to define massw PE with echocardiographic disorders, the cut-off val- 
ues of the RVEDD/LVEDD, the RVEDA’LVEDA and SPAP that yielded the highest dis- 
cnminating power were 0.5, 0.6 and 35 mmHg respectively, according to ROC curves. 
Echocardiographlc ROC curves analysis showed that the RVEDAILVEDA was the more 
accurate indicator of right ventricular obstruction. 
Conclusion: This echocardiographic study suggests that the right to left ventricular end- 
diastolic ratio using apical four-chamber view is the most accurate echocardiographic 
parameter of right ventriculal obstruction in acute PE. with a ratio higher than 0.6. 
1008-i 31 Bosentan Increases Warfarin Dosing Requirements in 
Pulmonary Hypertension 
Matthew P~ncus, Carolyn Corngan, Peter Macdonald. Christouher S. Havward, Anne 
Keogh, St. Vincent’s Hospital, Sydney, Australia 
Background: Bosentan is the first oral agent to have proven effectiveness in pulmonary 
arterial hypertension. Warfarin also has proven benefits and is used in most patients with 
this condition. Data from a trial in healthy volunteers have suggested that bosentan can 
reduce prothrombin time in those taking warfar~n. This is the first study examining the 
effect of bosentan on the International Norm&sing Ratlo (INR) in any patient population. 
Methods: A retrospective observational study was performed of 19 wadarinised patients 
wth pulmonary hypertension who had been enrolled in an open label bosentan study. 10 
of the patients had primary pulmonary hypertension, 4 had chronic thromboembollc pul- 
monary hypertension, 3 had scleroderma and 2 had systemic lupus erythematosis. Their 
mean age was 40 years. The patients had their INR and warlarin dose recorded at base- 
line, after a month of bosentan at a dose of 62.5 mg twice daily, and after an additional 
month at a dose of 125 mg twice daily.Warfar!n doses were adjusted at the discretion of 
the patients’ general practitioners with a target range of 2.3. 
Results: There was an increase in the mean wadarin dose from 3.6 (SD 1.4) to 4.4 (SD 
1.5) after a month on the low bosentan dose and a further increase to 4.6 (SD 1.5) after a 
month on the higher dose. This increase was statistically significant (p<O.Ol). The corre- 
spondmg INRs were 2.5 at baseline, 2.6 after 1 month and 2.5 after 2 months. These 
were not significantly different. 
Conclusion: When warfarinised patients with pulmonary hypertension are starled on 
bosentan, they require a higher dose of waiiarin to maintain a steady INR. 
1008-l 32 The Utility of Sildenafil in Infants With Pulmonary 
Hypertension 
P. V. Suresh A. Varma, R. Sharma, C. John, Sunita Maheshwari, Narayana -I 
Hrudayalaya, Bangalore, India 
Background: The treatment of pulmonary artery hypertension (PAH) has been limited by 
the paucity of effective and affordable oral therapy. The use of sildenafil in adults with 
PAH has been reported. However, its efficacy in the pediatnc population has not been 
fully evaluated. We used It as a last resort in 3 infants with pulmonary hypertension and 
the results are reported. 
Methods: Infants with PAH unresponsive to conventional therapy available at our center 
were considered for sildenafil therapy. Parental consent was obtained in accordance with 
the hospital protocol for Investigational drugs. The clinical status and echocardiographic 
indicators of PAH such as tricuspid regurgitation (TR) jet gradient and the direction of the 
patent ductus arteriosus (PDA) were assessed. As we were using an investigational drug 
as a ‘last-ditch’ effort, cardiac catheterization data was not obtained. Sildenafil was 
started and echo evaluation repeated at 24 hours, 46 hours and 1 week. 
Results: Between March to August 2002, 3 infants at our institution had severe PAH 
requiring therapeutic intervention. The age range was 15 days to 9 months and weight 
was 2.5 to 6.5 kg. The diagnoses included a postoperative PDA ligation (n=l) and 2 
infants with persistent primary pulmonary hypertension with no identifiable cardiac 
cause. In 2 infants the TR jet gradient decreased from 75.60 to 20-30 mmHg within 24 
hours of starting sildenafil, and the patients were rapidly weaned off the ventilator and 
oxygen. In the 9 month old no response was noted initially or at 1 week. 
Conclusion: Oral sildenafil appears to be especially effective in neonates with pulmonary 
hypertension. If it works, the effect appears to be dramatic and occurs within 24-46 
hours. Further prospective trials to assess its effect, and decide on dosing schedules, are 
needed. 
1008-l 33 Survival After Diagnosis of Primary Pulmonary 
Hypertension: Single Center Experience With 
Transplantation and Preoperative Therapy With 
Prostacyclin Analogues 
Michael Dandel Dagmar Kemper, Yuguo Weng, Sead Mulahasanovic, Hans B. 
Lehmkuhl, Bernhard Schulz, Martin Bettmann, Susanne Kapell, Heidrun Bbttcher, 
Manfred Hummel, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany 
Background: Without treatment, patients with primary pulmonary hypertension (PPH) 
survive less than 3 years after diagnosis. Our study summarized over 11 years clinical 
experience in PPH therapy. 
Methods: We reviewed our institution’s experience with both transplantation (TX) and 
preoperative prostanoid therapy. The analysis included all PPH patients (56 women, 27 
men) referred by our institution for TX between 1991 and 2002. TX was performed in 36 
of these patients (21 heart-lung and 15 double-lung TX). Since 1996 we used a stepwise 
therapeutic regimen which included beraprost tablets or iloprost inhalation !n the earlier 
stages of the disease and intravenous iloprost infusion in NYHA class IV patbents. 
Results: The actuarial survival since diagnosis for all 85 evaluated patients was 90.5% at 
1 year, 69.4% at 3 years, 62.5% at 10 years, and the mean suwival time since diagnosis 
was 138 * 17 months. Of these patients, only 15 underwent neither vasodilator therapy 
with prostanoids (for various reasons) nor transplantation (8 patients died before TX, 7 
are still on the waiting ltst). The other 70 were treated with prostanoids or with transplan- 
tation or with both. The actuarial suwival after PPH dtagnosis in this group reached 
74.1% at 3 years and 66.7% at 10 years. The 3 year actuarial survival since diagnosis 
was 76.4% in patients treated preoperatively with prostanolds and 56.25% in those with- 
out prostanoids. The mortality rate on the waiting list for TX was 11.5% in the prostanoid 
group and 26.1% in the group without prostanoid treatment. The actuarial post-transplant 
suw~val was 44.5% at 5 years and 42.9% at 8 years. At the present time, 27 patients are 
being treated with prostanoids. Listing for transplantation could be postponed during this 
treatment of 25.2 f 12.6 months duration in 26 patients, although the mean time since 
diagnosis reached already 56.0 254.4 months. 
Conclusions: Since use of prostanolds increases the 3.year actuarial SUIVIV~I after PPH 
diagnosis and reduces the mortality rate on the waiting list, it is an effective bridging-to- 
transplant therapy. Transplantation in combination with prior prostanoid administration 
provides important su~~val benefits for PPH patients. 
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1009-117 Clopidogrel Nonresponders Discovered During Point- 
of-Care Platelet Aggregation Testing 
Wet C. Lau Charlene J. New. Paul B. Watkins, David G. Carville, Kirk E. Guyer, Eric R. 
Bates, University of Michigan Health System, Ann Arbor, MI. Indiana Unwersity, South 
Bend, IN 
Background:The phenomenon of aspirin resistance has recently been recognized. Dur- 
ing the course of determlning that cytochrome P450 (CYP) 3A4 is the primary catalyst for 
the metabolic activation of the prodrug clopidogrel, it was obsewed that the effectiveness 
of a loading dose of clopidogrel varied I” healthy volunteers. 
